Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML

Inclusion Criteria: 1. Patients with acute myeloid leukemia (AML) diagnosed by bone marrow morphology and immunophenotyping (in line with WHO 2016 diagnostic criteria); 2. No previous anti-acute leukemia treatment (including demethylating drugs), except hydroxyurea and Leukocyte apheresis; 3. Exclude acute promyelocytic leukemia (APL) at the bone marrow morphology or molecular level; 4. Age 60-80 years old; 5. Aspartate aminotransferase (ALT), alanine aminotransferase (AST), and alkaline phosphatase (ALP)≤ 3×upper limit of normal (ULN), serum bilirubin≤ 1.5×ULN; serum creatinine≤ 2.0×ULN; serum heart rate≤ 2.0×ULN; 6. LVEF determined by echocardiography≥ 50%; 7. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2; 8. Obtain informed consent signed by the patient or legal representative. Exclusion Criteria: 1. Acute promyelocytic leukemia, myeloid sarcoma, accelerated phase and blast of chronic myeloid leukemia; 2. Patients with relapsed AML; 3. Allergy to any drug involved in the program; 4. Pregnant, lactating women and patients of childbearing age who are unwilling to take contraceptive measures; 5. The liver and kidney functions are obviously abnormal, exceeding the inclusion criteria; 6. Structural heart disease, such as uncontrolled or symptomatic arrhythmia, congestive heart disease, heart failure or myocardial infarction within 6 months prior to screening, resulting in clinical symptoms or abnormal cardiac function; 7. Suffering from other malignant tumors at the same time; except for the following cases: ①Have received treatment for the purpose of cure, and have no known active malignance for ≥5 years before enrollment; ② Adequately treated non-melanoma skin cancer or malignant lentigo with no signs of disease (even if less than 3 years before randomization); ③ Adequately treated carcinoma in situ with no signs of disease (even if less than 3 years before randomization); 8. AIDS patients, syphilis patients, active type Hepatitis B (HBV-DNA detectable) patients, and Hepatitis C patients; 9. Any concurrent medical condition or disease (such as active systemic infection) that may interfere with study procedures or results, or which, in the judgment of the investigator, poses a risk to participation in this study； 10. Inability to understand or comply with the research protocol; 11. Received major surgery within 4 weeks before randomization; 12. Participate in other clinical investigators at the same time one month before enrollment.